Jennifer Boggs

Atlanta

Assistant Managing Editor at BioWorld

Assistant Managing Editor at BioWorld MedTech

Featured in: Favicon

bioworld.com Favicon

jamanetwork.com Favicon

realsimple.com Favicon

acpjournals.org Favicon

healio.com Favicon

jpeds.com

Articles

Kymera’s phase I data lead big week for STAT6 space

3 days ago | bioworld.com | Jennifer Boggs

Kymera’s phase I data lead big week for STAT6 spaceIt’s a good week to be working on drugs targeting STAT6. Kymera Therapeutics Inc.’s, KT-621, the first oral STAT6 degrader candidate to enter the clinic, surpassed expectations with impressive safety, pharmacokinetic and biomarker data from a phase I trial, while potential fast-followers from Nurix Therapeutics Inc. and Recludix Pharma Inc. advanced via respective partnerships with Sanofi SA.
Redemption for Lyra as second phase III rhinosinusitis trial hits goal

5 days ago | bioworld.com | Jennifer Boggs

Redemption for Lyra as second phase III rhinosinusitis trial hits goalShares of Lyra Therapeutics Inc. soared more than 310% on data from its second phase III trial testing drug-device candidate LYR-210 in patients with chronic rhinosinusitis, with results from the Enlighten 2 study showing statistical significance on primary and key secondary endpoints and offering hopes of a regulatory pathway ahead. BioWorld BioWorld MedTech Clinical Inflammatory Small molecule Combination drug-device U.S.
Consistency not enough? Summit falls on lung cancer survival miss

1 week ago | bioworld.com | Jennifer Boggs

Consistency not enough? Summit falls on lung cancer survival missFor the second time in as many months, the lack of statistically significant overall survival data sent shares of Summit Therapeutics Inc. sliding, despite otherwise positive findings for PD-1/VEGF bispecific candidate ivonescimab in non-small-cell lung cancer.
HHS terminating Moderna’s $590M grant for flu vaccines

1 week ago | bioworld.com | Jennifer Boggs

HHS terminating Moderna’s $590M grant for flu vaccinesThe funding boost Moderna Inc. had expected via a roughly $590 million Biomedical Advanced Research and Development Authority award now looks to be off the table. The company disclosed May 28 that the U.S. Department of Health and Human Services (HHS) said it will terminate the award for late-stage development and right to purchase pre-pandemic influenza vaccines. BioWorld Regulatory Infection Vaccine U.S. Policy
Lilly adds non-opioid painkiller to pipeline in $1B Siteone buyout

1 week ago | bioworld.com | Jennifer Boggs

Lilly adds non-opioid painkiller to pipeline in $1B Siteone buyoutFour months after Vertex Pharmaceuticals Inc.’s U.S. FDA nod for Journavx (suzetrigine) as the first drug targeting NaV1.8 for treating pain, Eli Lilly and Co. is joining the potential competition via a buyout of Siteone Therapeutics Inc., a privately held firm developing small-molecule sodium channel inhibitors, including a phase II-ready NaV1.8 inhibitor. BioWorld Deals and M&A Neurology/psychiatric Small molecule U.S.
Apnimed’s oral sleep apnea candidate hits phase III endpoints

2 weeks ago | bioworld.com | Jennifer Boggs

Apnimed’s oral sleep apnea candidate hits phase III endpointsMirroring results reported in a phase IIb study, Apnimed Inc.’s first of two pivotal trials testing AD-109 as an oral therapy in obstructive sleep apnea hit primary and secondary endpoints. Should similar findings emerge from a second phase III trial, expected to read out in a couple of months, the privately held firm anticipates a U.S. NDA filing in early 2026. BioWorld BioWorld MedTech Clinical Neurology/psychiatric Small molecule U.S.
Biomarin snags potential ‘first-in-disease’ ERT in $270M Inozyme buy

3 weeks ago | bioworld.com | Jennifer Boggs

Biomarin snags potential ‘first-in-disease’ ERT in $270M Inozyme buyIt’s been a big week for Inozyme Pharma Inc. On the heels of a promising interim readout for phase III-stage enzyme replacement therapy (ERT) candidate INZ-701 in ENPP1 deficiency, the firm agreed to be acquired by Biomarin Pharmaceuticals Inc. in a deal valued at about $270 million, putting the rare disease ERT in the hands of an experienced commercial team. BioWorld Deals and M&A Endocrine/metabolic Enzyme U.S.
GSK pays $1.2B up front for Boston Pharma’s efimosfermin in MASH

3 weeks ago | bioworld.com | Jennifer Boggs

GSK pays $1.2B up front for Boston Pharma’s efimosfermin in MASHOnly a few days out of the European Association for the Study of the Liver annual meeting, the metabolic dysfunction-associated steatohepatitis (MASH) space continues to grab headlines, with GSK plc shelling out $1.2 billion up front to acquire phase III-ready efimosfermin alfa in a deal with Boston Pharmaceuticals Inc. that could end up totaling about $2 billion. BioWorld Deals and M&A Endocrine/metabolic Protein Europe U.S.
Theriva’s VCN-01 improves survival in phase IIb pancreatic cancer trial

1 month ago | bioworld.com | Jennifer Boggs

Theriva’s VCN-01 improves survival in phase IIb pancreatic cancer trialTheriva Biologics Inc.’s stroma-targeting oncolytic virus approach yielded positive findings in metastatic pancreatic ductal adenocarcinoma, with the top-line readout of phase IIb data showing VCN-01 (zabilugene almadenorepvec) in combination with chemotherapy bested chemotherapy alone on primary and secondary endpoints, which included overall survival. BioWorld Clinical Cancer Oncolytic Europe U.S.
Regulus’ rare kidney disease drug draws Novartis in potential $1.7B buyout

1 month ago | bioworld.com | Jennifer Boggs

Regulus’ rare kidney disease drug draws Novartis in potential $1.7B buyoutRegulus Therapeutics Inc. CEO Jay Hagan told investors in a January call the company had no interest in “simply out-licensing” rights to lead candidate farabursen, an oligonucleotide targeting autosomal dominant polycystic kidney disease set to start phase III testing on a path to a potential accelerated approval.